Bio-Techne stock is trading -15.07% below its average target price of $83.55 after dropping -9.5% during today's morning session. Analysts are giving the Large-Cap Biotechnology company an average rating of buy and target prices ranging from $65.0 to $95.0 per share.
The stock has an average amount of shares sold short at 3.1%, and a short ratio of 3.24. The company's insiders own 0.97% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 102.0% of Bio-Techne's shares being owned by this investor type.
Institutions Invested in Bio-Techne
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 12% | 18,272,433 | $1,296,611,828 |
| 2024-03-31 | Blackrock Inc. | 11% | 17,745,977 | $1,259,254,511 |
| 2024-03-31 | State Street Corporation | 4% | 6,368,887 | $451,936,215 |
| 2024-03-31 | Price (T.Rowe) Associates Inc | 4% | 5,746,119 | $407,744,598 |
| 2024-03-31 | BAMCO Inc. | 3% | 4,998,210 | $354,672,977 |
| 2024-03-31 | Morgan Stanley | 3% | 4,190,278 | $297,342,123 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 3,838,210 | $272,359,378 |
| 2024-03-31 | Neuberger Berman Group, LLC | 2% | 3,574,819 | $253,669,152 |
| 2024-03-31 | Df Dent & Co Inc | 2% | 3,397,002 | $241,051,258 |
| 2024-03-31 | Ameriprise Financial, Inc. | 2% | 3,281,069 | $232,824,653 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Bio-Techne.
